Inclusion Criteria:

1. Patients 18 years old or older, of either sex, with a diagnosis of limited small cell
lung cancer.

2. Patients with an ECOG functional state less than or equal to 2.

3. Informed consent to participate in the study.

4. Patients with a platelet count above 100,000/microlitre with no hemorrhagic
symptomatology.

Exclusion Criteria:

1. Curative or palliative surgery as the initial treatment of their neoplastic
condition.

2. Patients with an active hemorrhage in the past two months, organic lesions
susceptible to bleeding (e.g. active peptic ulcer, hemorrhagic cerebrovascular
accident, aneurysms), history of clinically evident hemorrhagic episodes, major
surgery in the past month, outstanding clinically hemoptysis or an increased risk of
bleeding due to any homeostatic alteration that contraindicates anticoagulant
therapy.

3. Known hypersensitivity to LMWH, heparin or substances of porcine origin.

4. Patients with hypersensitivity to the chemotherapeutic agents used in this protocol
that makes it impossible to use the antitumoral regime indicated in this protocol
(cisplatin or carboplatin and etoposide), i.e. hypersensitivity to cisplatin and
carboplatin or hypersensitivity to etoposide.

5. Patients with congenital or acquired bleeding diathesis.

6. Damage to/ or surgical interventions of the central nervous system, eyes and ears
within the past 6 months.

7. Acute bacterial endocarditis or slow endocarditis.

8. Patients with a history of heparin-associated thrombocytopenia or with a current
platelet count < 100,000/mm3

9. Patients with severe renal failure (serum creatinine over 2 mg/dl) or hepatic
insufficiency (with values of AST and/or ALT > 5 times the normal value established
in the reference range of the local hospital laboratory).

10. Severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic
blood pressure above 120 mmHg).

11. Women who are pregnant or breast-feeding, or with the possibility of becoming
pregnant during the study.

12. Patients with suspected inability/or inability to comply with treatment and/or
complete the study.

13. Patients who are participating in another clinical trial or have done so in the past
30 days.

14. Patients with a life expectancy less than 3 months.

15. Patients on treatment with anticoagulants or who have been on treatment during three
months before the diagnosis of the tumor.